Evidence map›Paper›PMID 40109866›Full record

ReviewOncology research2025

T-cell prolymphocytic leukemia, a case report and review of the literature.

Luis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel JUáREZ-Salcedo, Javier Loscertales, Eva Arranz, Jimena Cannata-Ortiz, Javier Ortiz, Maria JOSé LóPEZ DE LA Osa, ADRIáN Alegre, Samir Dalia

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luis Manuel GONZáLEZ-RODRíGUEZHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Luis Miguel JUáREZ-SalcedoHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Javier LoscertalesHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Eva ArranzHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Jimena Cannata-OrtizHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Javier OrtizHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Maria JOSé LóPEZ DE LA OsaHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
ADRIáN AlegreHematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
Samir DaliaHematology/Oncology, Mercy Clinic Oncology and Hematology-Joplin, Misouri, MO 64804, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-prolymphocytic leukemia is a rare and aggressive hematological malignancy characterized by the clonal proliferation of mature lymphoid T-cells. The pathogenesis of T-PLL is closely linked to specific chromosomal abnormalities, primarily involving the proto-oncogene T-cell leukemia/lymphoma 1 gene family. Recent advancements in molecular profiling have identified additional genomic aberrations, including those affecting the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This case report presents a patient with T-prolymphocytic leukemia whose cytogenetic and molecular analysis revealed a t(X;14)(q28;q11.2) translocation and a

Indexed as

Leukemia, Prolymphocytic, T-CellFemaleHematopoietic Stem Cell TransplantationHumansMiddle AgedMutationProto-Oncogene MasSTAT5 Transcription FactorTranslocation, GeneticMAS1 protein, humanProto-Oncogene MasSTAT5B protein, humanSTAT5 Transcription FactorAlemtuzumabJAK/STATMTCP1STAT5BT-prolymphocytic leukemia (T-PLL)

Identifiers

PMID40109866
PMCPMC11915055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.